Bacterial toxins are known to be effective for cancer therapy. Clostridium perfringens enterotoxin (CPE) is produced by the bacterial Clostridium type A strain. The transmembrane proteins claudin-3 and -4, often overexpressed in numerous human epithelial tumors (for example, colon, breast, pancreas, prostate and ovarian), are the targeted receptors for CPE. CPE binding to them triggers formation of membrane pore complexes leading to rapid cell death. In this study, we aimed at selective tumor cell killing by CPE gene transfer. We generated expression vectors bearing the bacterial wild-type CPE cDNA (wtCPE) or translationoptimized CPE (optCPE) cDNA for in vitro and in vivo gene therapy of claudin-3-and -4-overexpressing tumors. The CPE expression analysis at messenger RNA and protein level revealed more efficient expression of optCPE compared with wtCPE. Expression of optCPE showed rapid cytotoxic activity, hightened by CPE release as bystander effect. Cytotoxicity of up to 100% was observed 72 h after gene transfer and is restricted to claudin-3-and -4-expressing tumor lines. MCF-7 and HCT116 cells with high claudin-4 expression showed dramatic sensitivity toward CPE toxicity. The claudin-negative melanoma line SKMel-5, however, was insensitive toward CPE gene transfer. The non-viral intratumoral in vivo gene transfer of optCPE led to reduced tumor growth in MCF-7 and HCT116 tumor-bearing mice compared with the vector-transfected control groups. This novel approach demonstrates that CPE gene transfer can be employed for a targeted suicide gene therapy of claudin-3-and -4-overexpressing tumors, leading to the rapid and efficient tumor cell killing in vitro and in vivo.
INTRODUCTION
Cancer is still one major target for gene therapy due to the high incidence. 1 Success for cancer gene therapy highly depends on the choice of the appropriate therapeutic gene. 2, 3 Bacterial toxins are attractive candidates, which possess efficient cell killing capacity. 4 Particularly for the treatment of refractory tumors, use of these toxins represents an applicable option and was tested in vitro and in vivo to treat various cancers, and have also been efficiently used in gene therapeutic applications. [5] [6] [7] [8] The most extensively used toxins are diphteria toxin (Corynebacterium diphteriae) and Pseudomonas exotoxin A (Pseudomonas aeruginosa), which both inhibit protein synthesis by specific ribosylation of elongation factor-2. 4, 9 The two toxins were used for the treatment of prostate, pancreatic, ovarian, lung carcinoma and glioblastoma with promising therapeutic efficacies, and exerted also therapeutic efficacy in gene therapy approaches. [5] [6] [7] [8] [10] [11] [12] [13] [14] Alternatively, the pore-forming bacterial toxins streptolysin O (Streptococcus pyrogenes) and Clostridium perfringens enterotoxin (CPE) came into focus as promising cancer therapeutics. [15] [16] [17] [18] CPE is produced by the anaerobic gram-positive Clostridium perfringens type A strain, known to cause food poisoning. 19 CPE is a 35-kDa protein, which increases cell membrane permeability by formation of large prepore complexes. These insert into the plasma membrane, leading to the loss of osmotic equilibrium and cell death. [20] [21] [22] CPE binds to a subset of the claudin family of tight junction proteins, such as claudin-3 and -4, initially defined as CPE receptors. 23 The C-terminus of CPE permits this binding, whereas the N-terminus of CPE is rather associated with cytotoxicity. 24, 25 CPE preferentially binds to claudin-4 and with lower affinity to claudin-3. 23, 26 Claudin-3 and -4 regulate paracellular permeability, maintain epithelial cell polarity and are often overexpressed in epithelial tumors, such as colon, breast, pancreas, prostate, ovarian or endometrial cancer. [27] [28] [29] [30] [31] [32] Thus, particularly these two claudins are attractive targets for the selective CPE treatment of solid tumors. Application of recombinant CPE protein leads to the dose-dependent rapid eradication of claudin-4-or claudin-3-overexpressing pancreas, breast or colon cancer cells in vitro and in vivo. 17, 18, [33] [34] [35] [36] [37] The intratumoral in vivo application of recombinant CPE did not induce toxinassociated side effects, supporting its great therapeutic potential. However, these approaches require repeated, almost continuous regional or loco-regional application of recombinant CPE at doses ranging from 0.5 to 1.0 mg CPE per application to achieve therapeutic effects. 33, 36, 37 Furthermore, high interstitial pressure in the tumor might hinder proper distribution of externally applied CPE limiting its therapeutic action. 38 Alternatively, intratumoral gene transfer of CPE-expressing vectors could significantly improve duration of toxin availability associated with optimized intratumoral distribution and accumulation. Surprisingly, to date no such gene therapy study has been performed, which employs CPE gene transfer to directly exploit the cytotoxic activity of the expressed toxin. This is the first report describing the implementation of this approach. In this study, we cloned the CPE cDNA and optimized its sequence for human translation to express the toxin in human tumor cells. We demonstrate that CPE expression elicits rapid and selective tumor cell eradication in vitro and in vivo. Notably, CPE expression leads to the release of the toxin affecting non-transfected cells as bystander effect, which enhances toxin efficiency. The study supports the great potential of this novel suicide gene therapy, particularly for the local treatment of claudin-3-and -4-overexpressing epithelial tumors.
RESULTS
Claudin-3 and -4 expression in human tumor cell lines and sensitivity toward recombinant CPE As CPE action is strictly dependent on the presence of CPE-binding claudins, like claudin-3 and -4, we tested the human cancer cell lines SKMel-5, HCT116, MCF-7 and Pac-1 for claudin expression. We found high claudin-3 and -4 expression in MCF-7 cells at messenger RNA and protein level (Figure 1a ). HCT116 cells did express claudin-4 and -3 at lower level compared with MCF-7 cells, whereas Panc-1 cells did only express claudin-4 at detectable level ( Figure 1a ).
Semiquantitative analysis of the claudin-3 protein expression revealed that in SKMel-5 cells claudin-3 expression is 0%, in HCT116 cells 84% and in Panc-1 cells 0% in relation to the highest claudin-3-expressing MCF-7 cells (set as 100%). For claudin-4 expression, the level in SKMel-5 cells was 0%, in HCT116 cells 40% and in Panc-1 cells 14% in relation to the expression in MCF-7 cells (set as 100%). The melanoma line SKMel-5 did neither express claudin-3 nor claudin-4 and was therefore used as negative control in all in vitro experiments. The testing of the four cell lines for sensitivity toward treatment with the recombinant CPE demonstrates tight correlation between claudin-3 and -4 expression and sensitivity for the toxin (Figure 1b) . The claudin-3-and -4-expressing lines MCF-7 and HCT116 showed high sensitivity, starting at CPE concentrations of 0.05 to 0.1 mg ml À1 , and developed highest, 480%, toxicity at 0.25 mg ml À1 CPE. The Panc-1 cells were less sensitive toward toxin action due to the much lower claudin-4 expression. The claudin-negative SKMel-5 cells were completely insensitive toward CPE.
In vitro CPE expression and intracellular distribution For CPE expression, we generated the pCpG-wtCPE vector carrying the bacterial wtCPE cDNA and the pCpG-optCPE vector carrying the translation-optimized CPE (optCPE) cDNA. The two vector constructs were transfected into the four tumor cell lines and CPE expression was analyzed. At 24 h after transfection, we detected best, 4-to 40-fold improved messenger RNA and 3-to 36-fold improved protein expression of optCPE compared with wtCPE in all four lines ( Figure 2a) . We further determined changes in intracellular localization of the expressed optCPE protein by immunofluorescence in transfected MCF-7 and HCT116 cells with highest CPE expression (Figure 2b ). We observed rapid cytoplasmic toxin accumulation 12 h after transfection in both cell lines, which then changes to more membranous localization 24 h after transfection. This membranous localization of CPE remained, even 48 h after transfection, in dying or dead MCF-7 or HCT116 cells, in which cytoplasmic content is almost completely lost, reflected by loss of cytoplasmic Alexa 555 staining particularly in MCF-7 cells.
Selective cytotoxicity of CPE gene transfer and bystander effect by CPE release The demonstration of CPE cytotoxicity after gene transfer is of primary interest. For this, we transfected the wtCPE-and optCPEexpressing vectors into the four cell lines and determined cell viability. These experiments show high cytotoxicity particularly of optCPE in MCF-7 and in HCT116 cells 72 h after transfection with toxicity rates of 88% to almost 100% (Figure 3a) . In Panc-1 cells, optCPE exerts up to 60% cytotoxicity. Evaluation by light microscope shows massive monolayer disruption, cell flattening and attached empty cell remnants caused by CPE gene transfer (Figure 3b ). Due to the inefficient expression of wtCPE, levels of cytotoxicity are much lower in HCT116 and MCF-7 cells. The data again support correlation between claudin-4 and -3 expression and CPE toxicity. MCF-7 and HCT116 cells, which express claudin-4 and -3, are most sensitive for CPE gene transfer. Panc-1 cells with low-level claudin-4 and no claudin-3 expression, however, are less sensitive, in part also due to the lower transfection efficiency for this cell line ( Figure 2a , Table 1 ). The claudin-3-and -4-negative SKMel-5 melanoma cells did not respond to wtCPE or optCPE gene transfer pointing to the strict selectivity of this approach.
To analyze the claudin-specific action of CPE gene transfer in more detail, we established an isogenic pair of the claudin-3-and -4-negative SKMel-5 cells. We transfected the murine wild-type claudin-3 (wtCldn3) and a mutated claudin-3 (mutCldn3) variant into these cells and selected stably expressing clones (Figure 3c ). Treatment of the wtCldn3-transfected SKMel-5 clones with 100 ng ml À1 recombinant CPE permitted 55% toxicity compared with untransfected control cells, whereas the mutCldn3-transfected SKMel-5 cells remained as insensitive, as the untransfected SKMel-5 cells (Figure 3d ). We then transfected these clones with the optCPE-expressing vector and with the empty vector, and observed strong toxicity of 64% in the wtCldn3-expressing cells compared with the vector-transfected controls (Figure 3e ). By contrast, the mutCldn3-expressing cells did not respond to the optCPE transfection. These data support that the CPE gene transfer-mediated toxicity specifically depends on claudin expression and on the CPE-binding motif (including N148 and L150) in the extracellular loop 2 of claudins.
In all these experiments, we observed a much higher CPE-mediated toxicity, as would be expected by the transfection rate of 40 to 70% (Table 1 ). This suggests that CPE might be released into the medium affecting also non-transfected tumor cells as bystander effect. To prove this, we determined the presence of CPE in a medium of transfected MCF-7 and HCT116 cells. We observed release of CPE into the medium 24 and 48 h after transfection (Figure 4a ). Quantitation of the released toxin by CPE-ELISA (enzyme-linked immunosorbent assay) confirmed its continued presence over time of up to 34 ng ml À1 liberated from MCF-7 cells and up to 468 ng ml À1 released from HCT116 cells (Table 2) . To test if released CPE still has toxic activity, we added the medium collected 48 h after transfection to the respective non-transfected cells (Figure 4b) . The cytotoxicity assay clearly shows dramatic, up to 92%, cytotoxicity after 72 h incubation in HCT116 and about 72% cytotoxicity in MCF-7 cells. Addition of the HCT116 supernatants, however, left SKMel-5 cells unaffected. This strongly supports that the bystander effect is associated with the CPE gene transfer and causes escalation in toxicity. The analysis of optCPEtransfected SKMel-5 melanoma cells revealed that these cells not only accumulate CPE with time in the cytoplasm, as shown for MCF-7 and HCT116 cells, but also release biologically active CPE into the medium (Figures 4c and d) . Therefore, release of CPE into the medium by transfected cells seems to be independent of CPE cytotoxicity and of claudin-3 or -4 expression.
Mechanism of cytotoxicity in CPE-transfected tumor cells
Due to the rapid cell killing of CPE gene transfer, analysis of the underlying death pathway was of interest. We determined the possible activation of apoptotic and necrotic pathways in optCPE-transfected MCF-7 and HCT116 cells with highest sensitivity toward CPE. Potential activation of capases 3 and 7 as apoptotic markers was analyzed 12, 24 and 48 h after transfection (Figure 5a ). The assay revealed no caspase 3 or 7 activation at any time in MCF-7 cells, possibly due to their rapid eradication. In contrast, late, up to 6-fold increase of caspase 3 and 7 activity was observed in HCT116 cells 24 to 48 h after transfection. Analysis of caspase 1 did not reveal its activation by CPE gene transfer (Figure 5b ). The FACS analyses of annexin-V, propidium iodide (PI)-stained cells however revealed 74% of PI positivity in HCT116 cells and 43% in PI positivity in MCF-7 cells 24 h after transfection. This represents a 2.3-or 3-fold increase in PI labeling, respectively (Figure 5c ). Annexin-V-positive cells were not detected in both cell lines. In addition, we analyzed release of lactate dehydrogenase (LDH) into the medium in optCPE-transfected MCF-7 and HCT116 cells (Figure 5d ). In both cell lines, 24 h after optCPE gene transfer a 42-fold increase in LDH release was detected, indicating CPE-mediated disruption of cell membranes. This coincides with the hightened release of CPE into the medium due to leakiness ( Figure 4 ). In addition, close evaluation of CPE-transfected MCF-7 or HCT116 cells in a light microscope shows necrotic appearance of lyzed attached cell remnants with pyknotic nuclei (Figure 4e ). These data suggest that CPE gene transfer preferentially initiates necrotic cell death.
In vivo expression of CPE and antitumoral efficacy after non-viral intratumoral CPE gene transfer First, we analyzed intratumoral optCPE expression after combined intratumoral in vivo jet injection and electroporation gene transfer. We determined efficient and continuous intratumoral expression of CPE protein from day 1 to 5 ( Figure 6a ). The immunohistochemistry shows spotted areas of strong CPE expression within the tumor tissues, as shown in representative sections collected at day 1 and 2 after gene transfer (Figure 6b ). These data indicate presence of CPE protein for at least 5 days after in vivo gene transfer. Therefore, the schedule for the therapeutic treatments was adjusted to repeated in vivo gene transfer applications with 7-day intervals. In CPE gene therapy experiments, optCPE-transfected MCF-7 tumors show significant (P¼0.0317) reduction in tumor growth compared with the vector-transfected control group (Figure 6c ). The average tumor size was reduced to 0.322±0.08 cm 3 of the treated group compared with an average size of 0.714 ± 0.12 cm 3 of controls, representing a 55% reduction in tumor size. This is associated with appearance of great areas of tumor necrosis due to CPE action (Figure 6d ). The extent of necrotic areas in comparison with the restricted areas of CPE expression (see Figure 6b ) suggests similar bystander CPE effects as observed in the in vitro experiments. The in vivo experiments in HCT116 colon carcinoma-xenotransplanted mice also showed significant reduction (P¼0.0317) in tumor volumes in the HCT116 tumors transfected with optCPE compared with the respective vector controls (Figure 6e) . Here, the average tumor volume was reduced to 1.09 ± 0.42 cm 3 of the treated group compared with an average size of 3.16±0.65 cm 3 of controls, representing a 64% reduction in tumor size. Evaluation of HE-stained sections of optCPE-transfected tumors revealed large necrotic areas in the tumors, as seen in the transfected MCF-7 tumors (Figure 6f ). The gene transfer experiments in the HCT116 model support that CPE transfection exerts antitumoral in vivo effects in different tumor models, and point to the therapeutic potential of CPE gene therapy. In parallel, we included an additional animal group, which was treated with intratumoral injections of recombinant CPE (recCPE) at the dose of 1.0 mg recCPE for six times in a 3-day interval, adapting the in vivo treatment schedules described earlier. 17, 18 The application of the recCPE did also reduce the tumor volumes to an average size of 1.97±0.36 cm 3 , representing a 37.7% reduction (P¼0.1508) compared with the vector-transfected animal group (Figure 6e ). Throughout the course of the CPE gene transfer experiments no systemic toxicities, such as body weight loss, diarrhea, increase in body temperature, were observed.
DISCUSSION
Toxins have shown their therapeutic efficacy for cancer treatment both as recombinant proteins or as therapeutic genes in cancer gene therapy. [5] [6] [7] [8] 10 Apart from diphteria toxin and Pseudomonas exotoxin, other toxins such as streptolysin O and CPE came into focus. The two latter toxins are both pore-forming proteins, of which streptolysin O is rather unspecific, whereas CPE possesses specificity in action. [15] [16] [17] The targeted action of CPE is mediated by binding to a subset of claudins, mainly to claudin-3 and -4, which are frequently overexpressed in epithelial tumors. 22, 24, 25 This binding leads to disintegration of plasma membrane in association with rapid cytolysis of treated cells. 34 Several in vitro and in vivo studies demonstrated the antitumoral activity of recombinant CPE, limited by the need for frequent, repeated CPE application to achieve antitumoral effects. 17, 18 As a novel alternative Clostridium perfringens enterotoxin gene therapy W Walther et al approach, we were aiming at CPE gene therapy for improved and prolonged toxin action at lower dose as required for external CPE application. We demonstrated for the first time that CPE can be efficiently expressed in vitro and in vivo, dramatically improved by the translation optimized optCPE. More importantly, we showed that intracellular CPE expression and accumulation leads to effective tumor cell lysis in claudin-3-and -4-positive cells, with strong preference to claudin-4-overexpressing cells, while claudin-negative cells remained unaffected. 28 However, if claudin-3 was transfected into originally claudin-3-and -4-negative SKMel-5 cells, externally applied CPE and CPE transfection causes strong cytotoxicity. This supports the targeted action of CPE gene transfer. This approach is advantageous over other toxins used in cancer therapy, as they act on more ubiquitous, non-tumorspecific targets, such as E2F for diphteria toxin or membranous cholesterol for streptolysin O. 4, 16 For proper tumor targeting, modification of these toxins is required, for example, by creating fusion proteins as immunotoxins. 4 CPE has also been used to generate fusion proteins. Here, particularly the claudin-specific binding property of the CPE C-terminal domain was employed to target other toxins, such as diphteria toxin fragment A (DT-A), Pseudomonas aeroginosa exotoxin (PE) or TNF-a. [39] [40] [41] [42] [43] These approaches exploit CPE-mediated targeting to introduce the toxic proteins into tumor cells, and were shown to be effective in vitro and in vivo. These strategies aimed rather at improvement of cytotoxicities of DT-A, PE or TNF-a, than the toxicity of CPE itself. However, in vivo frequent applications of CPE and of CPE-fusion proteins were required to achieve therapeutic effects. [39] [40] [41] 43 In contrast, CPE as a sole full-length protein combines both strong target specificity and very efficient cytotoxicity, which is important for in vivo applications to achieve rapid tumor destruction. This study demonstrated that although CPE is produced inside the transfected cells, its outside action for pore formation and cell lysis is not hampered. Similar observations were made for streptolysin O gene transfer, where intracellular toxin expression leads to perforation of cell membranes verified by LDH release. 16 We also showed that intracellularly accumulated CPE causes membrane disruption associated with LDH relase in HCT116 and MCF-7 cells (Figure 4 ). More interestingly, we detected released biologically active CPE in the medium of transfected cells, although no signal peptide sequence was attached to CPE. Furthermore, in part, this release seems to be independent of CPE-mediated toxicity or of claudin-3 or -4 expression, as optCPE-transfected SKMel-5 cells also released CPE into the medium. This supports the concept of bystander toxicity by CPE gene transfer. This is strengthened by our observation that although our transfection affects 41 to 77% of the cells in the four tumor lines, in vitro CPE gene transfer eradicates up to almost 100% of the cells. Particularly for in vivo application of CPE gene therapy such bystander effect can be crucial for therapeutic efficacy. As we observed in vivo, our non-viral CPE gene transfer seems to affect greater than transfected areas, reflected by large proportions of necrosis in the transfected MCF-7 and HCT116 tumors ( Figure 6 ).
The mode of transfected CPE action regarding induction of apoptotic or non-apoptotic pathways was of interest. In this context, we did not detect rapid activation of caspases 3 or 7, as would be expected for apoptosis. Comparable effects were described for streptolysin O-transfected cells. 16 Only in HCT116 cells, delayed (48 h post transfection) release of capases 3 and 7 was detected. This can be attributed to the late action of liberated CPE on non-transfected HCT116 cells in a bystander effect. The data rather suggest induction of necrosis after CPE gene transfer. This is supported by LDH release of CPE-mediated pore formation, lack of annexin-V but high percentage of PI-positive cells and appearance of necrotic cell morphologies ( Figure 5 ), such as membrane rupture and attached empty cell remnants with pyknotic nuclei. 44, 45 The absence of caspase 1 activation excludes pyroptosis as potential death pathway, which is often associated with membrane breakdown. 46 In other reports for external application of low dose CPE induction of apoptosis was demonstrated, whereas for high dose CPE oncosis or necrosis has been described in colon carcinoma cells. 47 Our in vitro and in vivo experiments support that the intracellular accumulation of CPE after transfection induces necrosis. Other in vivo studies of external therapeutic application of recombinant CPE also reported strong necrosis in the tumor tissues. 33, [35] [36] [37] In conclusion, we report the successful tumor-targeted CPE gene therapy in vitro and in vivo. This approach efficiently eradicates tumor cells, and provides an attractive therapeutic option for the potential local treatment of refractory solid tumors (including unresectable tumor lesions, residual tumors or recurrences), originating from colon, mammary, pancreas or prostate cancer, which overexpress claudin-3 or -4. This might be of particular value if local control of the tumor disease by either non-viral or viral gene therapy is envisaged for possible clinical application, as numerous clinical studies have demonstrated applicability and efficacy of local cancer gene therapy. 48, 49 
MATERIALS AND METHODS

Cell cultivation
The human HCT116 colon, MCF-7 mammary carcinoma, Panc-1 pancreatic carcinoma and SKMel-5 melanoma cell line were grown in RPMI (PAA, Cölbe, Germany), 10% FCS (Biochrom, Berlin, Germany) at 37 1C, 5% CO 2 . Identity of the cell lines was confirmed by STR DNA typing (DMSZ, Braunschweig, Germany).
Generation of CPE-expressing vectors
The 990-bp CPE cDNA was PCR amplified from Clostridium perfringens DNA (kindly provided by MR Popoff, Institut Pasteur, Paris) and cloned into the Stu I/Bgl II sites of the pCpG-mcsG2 expression vector (Invivogen, San Diego, CA, USA), resulting in the wild-type CPE (wtCPE)-expressing construct pCpGwtCPE. For humanized translation, the CPE cDNA was codon optCPE (Entelechon GmbH, Regensburg, Germany) and cloned into the Stu I/Bgl II sites of the pCpG-mcsG2 vector, resulting in the pCpG-optCPE construct. In both constructs, a humanized Kozak consensus sequence was added to the CPE cDNA.
Transfection of human tumor cell lines
For transfection, 4Â10 5 cells were seeded into 6-well plates and transfected with 2 mg of the respective plasmid DNA using Fugene HD as recommended by the manufacturer (Roche Diagnostics, Mannheim, Germany). Transfection efficiency for each cell line was determined by transfection of the green fluorescent protein-expressing plasmid pEGFP-N1 (Clontech, Mountain View, CA, USA) and analysis using the FACScalibur (Becton Dickinson, San Jose, CA, USA) 48 h after transfection. Number of green fluorescent protein-expressing cells was quantified in three independent experiments and given as % green fluorescent protein-positive cells (Table 1) .
To generate the wtCldn3-and mutCldn3-expressing SKMel-5 cell clones as counterpart to the non-expressing wild-type SKMel-5 cells, the murine wtCldn3-expressing vector pECFP-N1cld3 and the mutCldn3-expressing vector pECFP-N1cld3mut were transfected. 50 The wtCldn3 was previously shown to have strong homology to the human claudin-3 and to specifically bind CPE, whereas the mutCldn3 variant harbors a mutation in the second extracellular loop (for Asn148: N148D; Leu150: L150A), which prevents CPE binding. The mutCldn3-expressing clone served as additional control to further support specificity of toxicity after CPE gene transfer. Stably expressing cell clones were selected in G418 (Invitrogen, Carlsbad, CA, USA)-containing medium. Claudin-3 expression was verified by western blot and clones were used for further experiments.
Quantitative real-time RT-PCR
Total RNA from cells was isolated using Trizol (Invitrogen) and reverse transcribed. Each real-time PCR was done using the LightCycler480 (Roche Diagnostics). The following primers were used: for claudin-3: forward 5¢-CT GCTCTGCTGCTCGTGTCC-3¢; reverse 5¢-TTAGACGTAGTCCTTGCGGTC GTAG-3¢; for claudin-4: forward 5¢-CCTCTGCCAGACCCATATAA-3¢; reverse 5¢-CACCGTGAGTCAGGAGATAA-3¢; for wtCPE: forward 5¢-GAAATCCT TGATTTAGCTGCTGC-3¢; reverse 5¢-AAGCTTTTGAGTCCAAGG GTATG-3¢ and for optCPE: forward 5¢-GCTAAGGAGGTGTTCCTCAT-3¢; reverse 5¢-GT GGCGTAGACCTTGTAGTA-3¢. Normalization was done with the housekeeping gene glucose-6-phosphate dehydrogenase using the hG6PDH Roche Kit.
Western Blot
For western blot analysis, 25 mg protein of lysates from cells or tissue cryosections were electrophorezed in 10% precast NuPAGE-gels (Invitrogen), 1 h at 200V, transferred to nitrocellulose membranes (Hybond-C Extra, Amersham, Freiburg, Germany) by semidry blotting (BioRad, Munich, Germany) at 20V, 1 h. Filters were blocked 1 h at room temperature (RT) in TBS (50 mM Tris, 150 mM NaCl, pH 7.5, 5% fat-free dry milk) and washed in TBST (0.05% Tween20 in TBS), 10 min at RT. Rabbit anti-CPE antibody (1:5000, Biogenesis, Poole, UK), rabbit anti-claudin-3 antibody (1:2000, Abcam, Cambridge, UK), rabbit anti-claudin-4 antibody (1:2000, Abcam) or mouse monoclonal anti-b-tubulin-IgM-antibody (1:500; BD Pharmingen, Heidelberg, Germany) was added over night at 4 1C and washed in TBST. Secondary antibody HRP-labeled anti-rabbit-IgG antibody (1:10 000, Promega, Madison, WI, USA) or goat anti-mouse IgM-antibody (1:5000, Sigma, Taufkirchen, Germany) was added for 1h, RT. Filters were washed in TBST and detection was done using ECL solution (Amersham) and exposed to Kodak X-Omat AR film (Kodak, Stuttgart, Germany).
Immunofluorescence and immunohistochemistry
For immunofluorescence, 5Â10 4 cells were seeded into 4-well chamber slides (Thermo Fisher, Rochester, NY, USA). The following day optCPE was transfected as described. Cells were washed with phosphate-buffered saline (PBS), fixed 15 min in 0.04% glutaraldehyde, permeabilized 10 min with 0.5% Triton X-100 in PBS and blocked 1 min with 5% bovine serum albumin in PBS at RT. Rabbit anti-CPE antibody (1:1000, Biogenesis) was added for 3 h, RT, and cells were washed with TBST. Alexa 488-labeled anti-rabbit-IgG (1:1500, Invitrogen) was added as secondary antibody, 1 h at RT. For staining of cytoplasm Alexa 555 (Invitrogen) and for staining of nuclei DAPI (Sigma) were used. Cells were evaluated in a Zeiss AxioObserver.Z1 fluorescence microscope (Zeiss, Jena, Germany).
For immunohistochemistry, tumor 7 mm cryosections were fixed 15 min in 0.04% glutaraldehyde, washed in PBS at RT, 20 min blocked with 1% H 2 O 2 , washed with PBS, permeabilized by 5% Triton X-100 in PBS 10 min at RT. Rabbit anti-CPE antibody (1:2000, Biogenesis) was added for 2 h, RT, and sections were washed in PBS for 5 min. HRP-labeled goat anti-rabbit antibody (1:500, Abcam) was added for 1 h, RT, cryosections were washed in PBS, incubated with diaminobenzidine, 2 min at RT, washed, counterstained for 1 min with hemalum (Roth, Karlsruhe, Germany), rinsed in water, covered with glycergel (DAKO, Hamburg, Germany) and evaluated in a light microscope (Zeiss).
Alamar-blue cytotoxicity assay
For sensitivity testing of the four cell lines toward recombinant CPE (R-Biopharm, Darmstadt, Germany), 5Â10 3 cells were seeded into 96-well plates, and 24 h later the toxin was added at different concentrations (0.05, 0.1, 0.15, 0.2 and 0.25 mg CPE per ml, which equals 1.4, 2.83, 4.24, 5.66 and 7.0 nM CPE) for 72 h. To determine cytotoxicity of CPE gene transfer, 1Â10 5 cells of all four tumor cell lines were transfected in 24-well plates using 2 mg DNA and Fugene HD as recommended by the manufacturer (Roche Diagnostics). As controls nontransfected and vector-transfected cells of the respective cell line were used.
In both settings, after 72 h Alamar-blue (Serotech, Düsseldorf, Germany) was added and adsorption was measured in triplicates in a microplate reader (Tecan, Crailsheim, Germany) at 620/560 nM. Values are expressed as percentage of untreated controls.
MTT cytotoxicity assay
The CPE-containing or control supernatants were harvested 48 h after transfection. To test biological activity of released CPE from transfected HCT116 or MCF-7 cells, MTT cytotoxicity assay was performed. For this, 5Â10 3 nontransfected HCT116 or MCF-7 cells were seeded into 96-well plates. After 24 h, 50 ml of supernatants from optCPE or vector (controls)-transfected HCT116 or MCF-7 cells was added to the respective non-transfected cells and incubated for 72 h. MTT (3-(4,5-dimethylthiazyol-2yl)-2,5-diphenyltetrazolium bromide (Sigma, 5 mg ml À1 ) was added and absorbance was measured in triplicates at 560 nm in a microplate reader (Tecan). Values are expressed as percentage of untreated controls.
CPE-specific ELISA
To quantify CPE in the supernatants 24 h and 48 h after optCPE transfection of HCT116 or MCF-7 cells, CPE-specific ELISA was performed. Supernatants (100 ml) were added to the 96-well Ridascreen CPE-ELISA plates (R-Biopharm) and detection was performed as recommended by the manufacturer. Recombinant CPE was used as standard at serial dilutions (0.4 to 25 ng CPE per ml). Measurements were done in duplicates at 450 nm in a microplate reader (Tecan). Values are expressed as ng CPE per ml supernatant.
Caspase 3, 7 and caspase 1 assays After transfection, supernatants of transfected cells were collected at indicated times (0 to 48 h), and caspase 3 and 7 activity was determined using the Apo-One kit (Promega) as recommended by the manufacturer. The caspase 1 activity was determined using the Caspase-1 color assay kit (Bio Vision, Mountain View, CA, USA) as recommended, and optical densities were measured in a microplate reader (Tecan) at 405 nm.
LDH release assay
After transfection, supernatants of transfected cells were collected at indicated times (0 to 48 h), and LDH release was determined using the Cytotoxicity detection kit (Roche Diagnostics) as recommended by the manufacturer.
FACScan analysis of apoptosis
For analysis of possible optCPE-mediated apoptosis, cells were harvested 12, 24 and 48 h after transfection and labeled using the Annexin-V fluor staining kit as recommended (Roche Diagnostics). Propidium-and Annexin-V-positive cells were quantified using the FACScalibur (Becton Dickinson).
In vivo CPE gene transfer
For establishment of subcutaneous tumors, 1Â10 7 MCF-7 cells were inoculated into female NMRI:nu/nu mice (n¼5 animals per group) or 1Â10 7 HCT116 cells were inoculated into female NMRI:nu/nu mice (n¼5 animals per group). All MCF-7 inoculated mice received an estradiol supplementation. At tumor size of 5Â5 mm, intratumoral non-viral in vivo gene transfer by combined jet injection and electroporation was performed in anesthetized animals. For this, 50 mg plasmid DNA of the respective vector construct was applied by 5 jet injections (jet injector, EMS Medical Systems SA, Nyon, Switzerland) of 10 ml per injection (1 mg DNAml À1 PBS) followed by electroporation of 5 pulses 200 V cm À1 20 ms (CUY21 EDIT; Sonidel, Dublin, Ireland). The in vivo gene transfer was performed three times at an interval of 7 days. Tumor volumes, body temperature and body weight were measured at indicated time points. Animals were killed for tumor removal and further analysis. All experiments were performed in accordance with the UKCCCR guidelines and approved by the responsible local authorities (State Office of Health and Social Affairs, Berlin, Germany). For treatment of HCT116 tumors, animals received six times intratumoral injections of 1.0 mg CPE (R-Biopharm) at 3-day intervals.
Statistical analysis
For statistical analyses of the in vitro experiments the Student's t-test was used, and for the analyses of the in vivo experiments the non-parametric Mann-Whitney test was used. Error values for the in vitro experiments are s.d. and for the in vivo experiments s.e.m.
